Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding

• References

• 1 Alberts MJ, Bernstein RA, Naccarelli GV, Garcia DA. Using dabigatran in patients with stroke: a practical guide for clinicians. Stroke 2012; 43: 271-279.
• 2 Fu W, Guo H, Guo J. et al. Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis. J Cardiovasc Med 2014; 15: 873-879.
• 3 Connolly SJ, Ezekowitz MD, Yusuf S. et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
• 4 Miyares MA, Kuyumjian Y, Eaves S, Dollard E. Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran. J Pharm Pract 2015; 28: 548-554.
• 5 Glund S, Stangier J, Schmohl M. et al. Safety, tolerability, and efficacy of Idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015; 386: 680-690.
• 6 Glund S, Moschetti V, Norris S. et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of Idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015; 113: 943-951.
• 7 Pollack CV, Reilly PA, Eikelboom J. et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373: 511-520.